Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy
Abstract
Aim: Real-world palonosetron effectiveness was evaluated in an antiemetic regimen with highly emetogenic chemotherapy (HEC). Patients & methods: In this Phase IV, prospective, multicenter observational study, HEC-treated cancer patients received palonosetron, a neurokinin 1 receptor antagonist, and dexamethasone. Primary objective was to assess complete response (CR) for acute (≤24 h), delayed and overall (≤120 h) chemotherapy-induced nausea and vomiting. Results: Of 159 patients, 65.4% had breast cancer, 64.8% received anthracycline (doxorubicin)-plus-cyclophosphamide-containing chemotherapy; 155 completed one HEC cycle. CR was 60.0% acute, 39.4% delayed and 34.8% overall, and then increased (all phases) in 69 patients completing four HEC cycles. Anthracycline (doxorubicin) plus cyclophosphamide-receiving patients had especially low CR. Conclusion: Even within a recommended three-drug antiemetic regimen, palonosetron may provide suboptimal chemotherapy-induced nausea and vomiting control with HEC in real-world settings.
Formats available
You can view the full content in the following formats:
References
Papers of special note have been highlighted as: • of interest; •• of considerable interest
1.
Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients’ quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. J. Clin. Oncol. 24(27), 4472–4478 (2006).
2.
Haiderali A, Menditto L, Good M, Teitelbaum A, Wegner J. Impact on daily functioning and indirect/direct costs associated with chemotherapy-induced nausea and vomiting (CINV) in a US population. Support. Care Cancer 19(6), 843–851 (2011).
3.
Van Laar ES, Desai JM, Jatoi A. Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers. Support. Care Cancer 23(1), 151–157 (2015).
4.
Sommariva S, Pongiglione B, Tarricone R. Impact of chemotherapy-induced nausea and vomiting on health-related quality of life and resource utilization: a systematic review. Crit. Rev. Oncol. Hematol. 99, 13–36 (2016).
• Comprehensive review outlining evidence of the effect of chemotherapy-induced nausea and vomiting (CINV) on patient's quality of life and its healthcare cost burden.
5.
NCCN. NCCN clinical practice guidelines in oncology: antiemesis – v3.2018 (2018). www.nccn.org/professionals/physician_gls/default.aspx.
• US clinical practice guidelines for the prevention and treatment of CINV.
6.
Roila F, Molassiotis A, Herrstedt J et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann. Oncol. 27(Suppl. 5), v119–v133 (2016).
• European clinical practice guidelines for the prevention and treatment of nausea and vomiting induced by moderately emetogenic chemotherapy.
7.
Aapro M, Gralla R, Herrstedt J, Molassiotis A, Roila F. MASCC/ESMO antiemetic guideline 2016 (2016). www.mascc.org/antiemetic-guidelines.
8.
Herrstedt J, Roila F, Warr D et al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Support. Care Cancer 25(1), 277–288 (2017).
• European clinical practice guidelines for the prevention and treatment of nausea and vomiting induced by highly emetogenic chemotherapy.
9.
Hesketh PJ, Kris MG, Basch E et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 35(28), 3240–3261 (2017).
• US clinical practice guidelines for the prevention and treatment of CINV.
10.
Aloxi (palonosetron HCl) injection for intravenous use, prescribing information. Eisai, Inc., NJ, USA (2015).
11.
Botrel TE, Clark OA, Clark L, Paladini L, Faleiros E, Pegoretti B. Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis. Support. Care Cancer 19(6), 823–832 (2011).
12.
Sancuso (granisetron transdermal system), prescribing information. ProStrakan, Inc., NJ, USA (2017).
13.
Sustol (granisetron) extended-release injection, for subcutaneous use, prescribing information. Heron Therapeutics, CA, USA (2017).
14.
Basch E, Prestrud AA, Hesketh PJ et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 29(31), 4189–4198 (2011).
15.
Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support. Care Cancer 20(1), 107–117 (2012).
16.
Geling O, Eichler HG. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J. Clin. Oncol. 23(6), 1289–1294 (2005).
17.
Aapro M, Molassiotis A, Dicato M et al. The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER). Ann. Oncol. 23(8), 1986–1992 (2012).
18.
Schnadig ID, Agajanian R, Dakhil C et al. APF530 (granisetron injection extended-release) in a three-drug regimen for delayed CINV in highly emetogenic chemotherapy. Future Oncol. 12(12), 1469–1481 (2016).
•• Phase III trial of granisetron extended-release subcutaneous versus ondansetron, each in a three-drug regimen, for the prevention of delayed CINV in patients receiving highly emetogenic chemotherapy.
19.
Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N. Engl. J. Med. 375(2), 134–142 (2016).
20.
Ng TL, Hutton B, Clemons M. Chemotherapy-induced nausea and vomiting: time for more emphasis on nausea? Oncologist 20(6), 576–583 (2015).
21.
Gralla RJ, Osoba D, Kris MG et al. Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J. Clin. Oncol. 17(9), 2971–2994 (1999).
22.
Ihbe-Heffinger A, Ehlken B, Bernard R et al. The impact of delayed chemotherapy-induced nausea and vomiting on patients, health resource utilization and costs in German cancer centers. Ann. Oncol. 15(3), 526–536 (2004).
23.
Schwartzberg LS, Modiano MR, Rapoport BL et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, Phase III trial. Lancet Oncol. 16(9), 1071–1078 (2015).
24.
Schnadig ID, Agajanian R, Dakhil C et al. APF530 versus ondansetron, each in a guideline-recommended three-drug regimen, for the prevention of chemotherapy-induced nausea and vomiting due to anthracycline plus cyclophosphamide-based highly emetogenic chemotherapy regimens: a post hoc subgroup analysis of the Phase III randomized MAGIC trial. Cancer Manag. Res. 9, 179–187 (2017).
25.
Hutton B, Clemons M, Mazzarello S, Kuchuk I, Skidmore B, Ng T. Identifying an optimal antiemetic regimen for patients receiving anthracycline and cyclophosphamide-based chemotherapy for breast cancer – an inspection of the evidence base informing clinical decision-making. Cancer Treat. Rev. 41(10), 951–959 (2015).
26.
Kolesar JM, Eickhoff J, Vermeulen LC. Serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting: therapeutically equivalent or meaningfully different? Am. J. Health Syst. Pharm. 71(6), 507–510 (2014).
27.
Yeh YC, Blouin GC, Reddy P. Evidence to support use of palonosetron over generic serotonin type 3-receptor antagonists for chemotherapy-induced nausea and vomiting. Am. J. Health Syst. Pharm. 71(6), 500–506 (2014).
28.
Aapro MS, Grunberg SM, Manikhas GM et al. A Phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy. Ann. Oncol. 17(9), 1441–1449 (2006).
29.
Saito M, Uomori T, Miura K et al. Comparison between 1st and 2nd generation serotonin receptor antagonists in triplet antiemetic therapy in breast cancer patients – according to recent multi-institutional double-blind randomized study. Support. Care Cancer 25(Suppl. 2), S21–S266; Abstract PS054 (2017).
30.
Matsumoto K, Takahashi M, Sato K et al. Palonosetron or granisetron for prevention of CINV in patients with breast cancer receiving dexamethasone and fosaprepitant following anthracycline plus cyclophosphamide (AC) regimen. J. Clin. Oncol. 33, Abstract 9598 (2015).
31.
Arevalo-Araujo R, O'Boyle E, Cooper W, Robertson PA. Recovery of complete antiemetic response with APF530 during treatment with moderately (MEC) and highly (HEC) emetogenic chemotherapy regimens in patients who failed palonosetron. J. Clin. Oncol. 31(15 Suppl.), Abstract e20569 (2013).
32.
Akynzeo (netupitant and palonosetron) capsules, (fosnetupitant and palonosetron) for injection, prescribing information. Helsinn Heathcare SA, Lugano, Switzerland (2018).
Information & Authors
Information
Published In
Copyright
© 2018 Lee S Schwartzberg.
History
Received: 5 September 2018
Accepted: 24 September 2018
Published online: 11 October 2018
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Real-world efficacy: intravenous palonosetron three-drug regimen for chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy. (2018) Journal of Comparative Effectiveness Research. DOI: 10.2217/cer-2018-0089
Export citation
Select the citation format you wish to export for this article or chapter.
Citing Literature
- Yanying Li, Yuming Wan, Xiaoyun Yang, Ping Chen, Yan Gui, Lang He, Yingwei Xie, Jing Tian, Ping Duan, Guangguo Liu, Yu Sun, Jiang Zhu, Two doses of fosaprepitant included prophylactic treatment for the three-day cisplatin-based chemotherapy induced nausea and vomiting, Journal of Cancer Research and Clinical Oncology, 10.1007/s00432-024-05766-7, 150, 6, (2024).
- Haohao Lu, Chuansheng Zheng, Bin Liang, Xiangwen Xia, Analysis of the Efficacy and Safety of Palonosetron Hydrochloride in Preventing Nausea And Vomiting After TACE: A Retrospective Analysis, Current Radiopharmaceuticals, 10.2174/0118744710261186231026062257, 17, 1, (46-54), (2024).
- Hang Zhang, Qiang Zeng, Tian Dong, Xinchuan Chen, Pu Kuang, Jian Li, Qiuhui Wu, Ting Liu, Ting Niu, Zhigang Liu, Jie Ji, Comparison of netupitant/palonosetron with 5-hydroxytryptamine-3 receptor antagonist in preventing of chemotherapy-induced nausea and vomiting in patients undergoing hematopoietic stem cell transplantation, Frontiers in Oncology, 10.3389/fonc.2023.1280336, 13, (2023).
- Yanying Li, Yu Sun, Bin Liu, Yi Sun, Ping Chen, Ke Xie, Yan Wang, Jiang Zhu, Prolonged administration of aprepitant improves cisplatin-based chemotherapy-induced nausea and vomiting, Future Oncology, 10.2217/fon-2021-1523, 18, 20, (2533-2543), (2022).
- Mastura Md Yusof, Matin Mellor Abdullah, Beng Khiong Yap, Soo Chin Ng, John Seng Hooi Low, Kai Seng Lam, Radzi Bin Ahmad Ahmad Badruddin, Christina Nye Bing Lai, Kah Liew Lau, Kwang Jeat Chong, Joel Gabriel Nonis, Muhammad Azrif Ahmad Annuar, Mohd Haris Fadzillah Bin Abdul Rahman, Real‐world multicenter study of the safety and efficacy of netupitant plus palonosetron fixed‐dose combination to prevent chemotherapy‐induced nausea and vomiting among Malaysian patients receiving moderately or highly emetogenic chemotherapy, Asia-Pacific Journal of Clinical Oncology, 10.1111/ajco.13667, 18, 4, (419-427), (2021).
- Laurent Zelek, Philippe Debourdeau, Hugues Bourgeois, Jean Philippe Wagner, Fabien Brocard, Claudia Lefeuvre-Plesse, Bruno Chauffert, Marianne Leheurteur, Jean-Baptiste Bachet, Hélène Simon, Didier Mayeur, Florian Scotté, A Pragmatic Study Evaluating NEPA Versus Aprepitant for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy, The Oncologist, 10.1002/onco.13888, 26, 10, (e1870-e1879), (2021).
- Rudolph M Navari, Gary Binder, Erminio Bonizzoni, Rebecca Clark-Snow, Silvia Olivari, Eric J Roeland, Single-Dose Netupitant/Palonosetron Versus 3-day Aprepitant for Preventing Chemotherapy-Induced Nausea and Vomiting: A Pooled Analysis, Future Oncology, 10.2217/fon-2021-0023, 17, 23, (3027-3035), (2021).
- Meinolf Karthaus, Gülten Oskay-Özcelik, Pia Wülfing, Carsten Hielscher, Dagmar Guth, Mark-Oliver Zahn, Elisa Flahaut, Jörg Schilling, Real-World Evidence of NEPA, Netupitant-Palonosetron, in Chemotherapy-Induced Nausea and Vomiting Prevention: Effects on Quality of Life, Future Oncology, 10.2217/fon-2020-0187, 16, 14, (939-953), (2020).
- Lee Schwartzberg, Rudolph Navari, Rebecca Clark-Snow, Ekaterine Arkania, Irena Radyukova, Kamal Patel, Daniel Voisin, Giada Rizzi, Rita Wickham, Richard J. Gralla, Matti Aapro, Eric Roeland, Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy, The Oncologist, 10.1634/theoncologist.2019-0527, 25, 3, (e589-e597), (2019).